JP3450080B2 - Health foods and pharmaceuticals containing procyanidin - Google Patents
Health foods and pharmaceuticals containing procyanidinInfo
- Publication number
- JP3450080B2 JP3450080B2 JP03752395A JP3752395A JP3450080B2 JP 3450080 B2 JP3450080 B2 JP 3450080B2 JP 03752395 A JP03752395 A JP 03752395A JP 3752395 A JP3752395 A JP 3752395A JP 3450080 B2 JP3450080 B2 JP 3450080B2
- Authority
- JP
- Japan
- Prior art keywords
- procyanidin
- production method
- water
- amount
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 title claims description 60
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 title claims description 37
- 229920002414 procyanidin Polymers 0.000 title claims description 37
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 title description 29
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 title description 29
- 239000003814 drug Substances 0.000 title description 5
- 235000013402 health food Nutrition 0.000 title 1
- XFZJEEAOWLFHDH-NFJBMHMQSA-N Epicatechin-(4beta->8)-catechin Natural products C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 claims description 29
- XFZJEEAOWLFHDH-UKWJTHFESA-N procyanidin B1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UKWJTHFESA-N 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000043 antiallergic agent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000000843 powder Substances 0.000 description 26
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 16
- 239000008101 lactose Substances 0.000 description 16
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 235000020357 syrup Nutrition 0.000 description 11
- 239000006188 syrup Substances 0.000 description 11
- 239000002994 raw material Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 244000215068 Acacia senegal Species 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 8
- 229920000084 Gum arabic Polymers 0.000 description 8
- 239000000205 acacia gum Substances 0.000 description 8
- 235000010489 acacia gum Nutrition 0.000 description 8
- 229960004926 chlorobutanol Drugs 0.000 description 8
- 239000008120 corn starch Substances 0.000 description 8
- 229940099112 cornstarch Drugs 0.000 description 8
- 239000004570 mortar (masonry) Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 7
- 235000005487 catechin Nutrition 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 150000001765 catechin Chemical class 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 5
- UQONAEXHTGDOIH-AWEZNQCLSA-N O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 Chemical compound O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 UQONAEXHTGDOIH-AWEZNQCLSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007937 lozenge Substances 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000006468 Thea sinensis Nutrition 0.000 description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
- 239000008116 calcium stearate Substances 0.000 description 4
- 235000013539 calcium stearate Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940105902 mint extract Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000020374 simple syrup Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 239000003871 white petrolatum Substances 0.000 description 4
- 229930013915 (+)-catechin Natural products 0.000 description 3
- 235000007219 (+)-catechin Nutrition 0.000 description 3
- 229930013783 (-)-epicatechin Natural products 0.000 description 3
- 235000007355 (-)-epicatechin Nutrition 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- -1 octadecyl silica gel Chemical compound 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- KEEKMOIRJUWKNK-CABZTGNLSA-N (2S)-2-[[2-[(4R)-4-(difluoromethyl)-2-oxo-1,3-thiazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(SC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F KEEKMOIRJUWKNK-CABZTGNLSA-N 0.000 description 1
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 1
- KJUCPVIVNLPLEE-UHFFFAOYSA-N 2,6-difluoro-n-[2-fluoro-5-[5-[2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]-2-propan-2-yl-1,3-thiazol-4-yl]phenyl]benzenesulfonamide Chemical compound S1C(C(C)C)=NC(C=2C=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C(F)=CC=2)=C1C(N=1)=CC=NC=1NC(C=N1)=CC=C1N1CCOCC1 KJUCPVIVNLPLEE-UHFFFAOYSA-N 0.000 description 1
- SSORSZACHCNXSJ-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound ClC=1C=C(C=CC=1Cl)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NCC(C)O SSORSZACHCNXSJ-UHFFFAOYSA-N 0.000 description 1
- KDDPNNXAZURUGP-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-3-[2-(piperidin-3-ylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound ClC=1C=C(C=CC=1Cl)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NC1CNCCC1 KDDPNNXAZURUGP-UHFFFAOYSA-N 0.000 description 1
- BWSQKOKULIALEW-UHFFFAOYSA-N 2-[2-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[2-(piperidin-3-ylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound FC1=C(C=C(C=C1)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NC1CNCCC1)C(F)(F)F BWSQKOKULIALEW-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- BVGDAZBTIVRTGO-UONOGXRCSA-N 3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-methoxy-6-[(2s)-2-methylpiperazin-1-yl]pyridin-3-yl]pyridin-2-amine Chemical compound C1([C@@H](C)OC=2C(N)=NC=C(C=2)C2=CN=C(C=C2OC)N2[C@H](CNCC2)C)=C(Cl)C=CC(F)=C1Cl BVGDAZBTIVRTGO-UONOGXRCSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- ONPGOSVDVDPBCY-CQSZACIVSA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ONPGOSVDVDPBCY-CQSZACIVSA-N 0.000 description 1
- BWJHJLINOYAPEG-HOTGVXAUSA-N 8-chloro-6-[(6-chloropyridin-3-yl)methyl]-3-[(1S,2S)-2-hydroxycyclopentyl]-7-methyl-2H-1,3-benzoxazin-4-one Chemical compound ClC1=C(C(=CC=2C(N(COC=21)[C@@H]1[C@H](CCC1)O)=O)CC=1C=NC(=CC=1)Cl)C BWJHJLINOYAPEG-HOTGVXAUSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- LRULVYSBRWUVGR-FCHUYYIVSA-N GSK2879552 Chemical compound C1=CC(C(=O)O)=CC=C1CN1CCC(CN[C@H]2[C@@H](C2)C=2C=CC=CC=2)CC1 LRULVYSBRWUVGR-FCHUYYIVSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- XFZJEEAOWLFHDH-RBYKNZBFSA-N Procyanidin B4 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@@H]1c1c(O)cc(O)c3c1O[C@H]([C@@H](O)C3)c1cc(O)c(O)cc1)c(O)cc(O)c2 XFZJEEAOWLFHDH-RBYKNZBFSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- ODUIXUGXPFKQLG-QWRGUYRKSA-N [2-(4-chloro-2-fluoroanilino)-5-methyl-1,3-thiazol-4-yl]-[(2s,3s)-2,3-dimethylpiperidin-1-yl]methanone Chemical compound C[C@H]1[C@@H](C)CCCN1C(=O)C1=C(C)SC(NC=2C(=CC(Cl)=CC=2)F)=N1 ODUIXUGXPFKQLG-QWRGUYRKSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- VZUGBLTVBZJZOE-KRWDZBQOSA-N n-[3-[(4s)-2-amino-1,4-dimethyl-6-oxo-5h-pyrimidin-4-yl]phenyl]-5-chloropyrimidine-2-carboxamide Chemical compound N1=C(N)N(C)C(=O)C[C@@]1(C)C1=CC=CC(NC(=O)C=2N=CC(Cl)=CN=2)=C1 VZUGBLTVBZJZOE-KRWDZBQOSA-N 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XFZJEEAOWLFHDH-VUGKQVTMSA-N procyanidin B4 Chemical compound C1([C@@H]2[C@@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-VUGKQVTMSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- OEBIHOVSAMBXIB-SJKOYZFVSA-N selitrectinib Chemical compound C[C@@H]1CCC2=NC=C(F)C=C2[C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)N1 OEBIHOVSAMBXIB-SJKOYZFVSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Confectionery (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、アレルギー疾患の治療
改善を目的とする抗アレルギー剤に関するものである。The present invention relates to the treatment of allergic diseases.
The present invention relates to an antiallergic agent for the purpose of improvement .
【0002】[0002]
【従来の技術】抗アレルギー作用を示す茶葉抽出成分と
してはエピガロカテキンガレート、エピガロカテキン、
エピカテキンガレートおよびエピカテキンなどが知られ
ている。このうち、カテキン類の抗アレルギー剤として
の利用は、特開平3−157330でエピガロカテキン
ガレートが示されている。2. Description of the Related Art Epigallocatechin gallate, epigallocatechin,
Epicatechin gallate and epicatechin are known. Among these, the use of catechins as antiallergic agents is disclosed in JP-A-3-157330, which is epigallocatechin gallate.
【0003】[0003]
【発明が解決しようとする課題】これまで我々は、茶葉
中の抗アレルギー成分についてヒスタミン遊離抑制作用
を指標に検討してきたが、上記カテキン類に加え、下記
一般式(1)で表されるカテキン重合体であるプロシア
ニジンにヒスタミン遊離抑制作用を見い出した。So far, we have investigated antiallergic components in tea leaves using histamine release inhibitory action as an index. In addition to the above catechins, catechins represented by the following general formula (1) We found that histamine release was suppressed in the polymer procyanidins.
【化1】
さらにプロシアニジンはエピガロカテキンガレートなど
の他のカテキンよりも安定性に優れていることから、プ
ロシアニジンの抗アレルギー剤としての本発明をなすに
至ったものである。[Chemical 1] Further, procyanidin is more stable than other catechins such as epigallocatechin gallate, and thus the present invention has been accomplished as an antiallergic agent of procyanidin.
【0004】[0004]
【課題を解決するための手段】本発明は、プロシアニジ
ンを含有することを特徴とする抗アレルギー剤である。
プロシアニジンは(+)カテキンあるいは(−)エピカ
テキンの重合体であり、プロシアニジンB−1、B−
2、B−3、B−4、B−5、B−6、B−7及びB−
8などが挙げられ、ウーロン茎茶をはじめ緑茶、ウーロ
ン茶、紅茶の葉などより単離精製されるものを利用する
ことができる。その精製法に関しては、Chemica
l & Pharmaceutical Bullet
in、31、3906−3914、(1983)を参考
にすることができる。すなわち、緑茶、ウーロン茎茶、
ウーロン茶、紅茶などに溶媒を加え抽出し、その抽出物
をクロマトグラフィーに供することによりプロシアニジ
ンを得ることができる。その抽出に用いる溶媒として
は、水、エタノール、メタノール、アセトン、酢酸エチ
ル、n−ブタノールあるいはそれらの混合溶媒などが挙
げられ、抽出は室温でも加熱してもよい。得られた抽出
物は、そのまま、クロマトグラフィーに供してもよい
が、水に溶解後、酢酸エチルやn−ブタノールなどで分
配抽出して得られる画分を供してもよい。そのクロマト
グラフィーとしては、液体クロマトグラフィーがよく用
いられ、その充填剤としてはイオン交換樹脂、シリカゲ
ル、オクタデシルシリカゲルなどが挙げられる。The present invention is an antiallergic agent characterized by containing procyanidins.
Procyanidin is a polymer of (+) catechin or (−) epicatechin, and procyanidins B-1 and B-
2, B-3, B-4, B-5, B-6, B-7 and B-
8 and the like, and those isolated and purified from oolong stem tea, green tea, oolong tea, black tea leaves and the like can be used. For the purification method, see Chemica.
l & Pharmaceutical Bullet
In, 31, 3906-3914, (1983) can be referred to. That is, green tea, oolong stem tea,
A procyanidin can be obtained by adding a solvent to oolong tea, black tea or the like, extracting the mixture, and subjecting the extract to chromatography. Examples of the solvent used for the extraction include water, ethanol, methanol, acetone, ethyl acetate, n-butanol or a mixed solvent thereof, and the extraction may be performed at room temperature. The obtained extract may be directly subjected to chromatography, or it may be dissolved in water and then fractionated by partition extraction with ethyl acetate or n-butanol. Liquid chromatography is often used as the chromatography, and examples of the packing material include ion exchange resins, silica gel, octadecyl silica gel and the like.
【0005】本発明で言う抗アレルギー剤にはキャンデ
ィー、ドロップ、錠菓、チューイングガム、カプセル、
飲料などが含まれる。また、本発明で言う抗アレルギー
剤は、経口投与もしくは筋肉内、皮内、皮下、静脈内、
下部体腔、皮膚などの非経口投与により投与される。さ
らに、本発明の抗アレルギー剤を製剤化するためには、
製剤の技術分野における通常の方法で錠剤、顆粒剤、散
剤、カプセル剤、シロップ剤、点眼剤、トローチ剤、注
射剤、坐剤、軟膏などの剤型が採用されうる。すなわ
ち、経口用固型製剤を調製する場合は主薬に賦形剤、さ
らに必要に応じて結合剤、滑沢剤、着色剤、矯味矯臭剤
などを加えた後、常法により錠剤、顆粒剤、散剤、カプ
セル剤、トローチ剤などとする。The antiallergic agents mentioned in the present invention include candy, drops, confectionery, chewing gum, capsules,
Beverages are included. In addition, the anti-allergy referred to in the present invention
The drug can be administered orally, intramuscularly, intracutaneously, subcutaneously, intravenously,
It is administered by parenteral administration to the lower body cavity or the skin. Furthermore, in order to formulate the antiallergic agent of the present invention ,
Dosage forms such as tablets, granules, powders, capsules, syrups, eye drops, troches, injections, suppositories, ointments and the like can be adopted by a conventional method in the technical field of formulation. That is, when preparing a solid preparation for oral use, an excipient, and if necessary, a binder, a lubricant, a colorant, a flavoring agent, etc. are added to the main drug, and then tablets, granules, Powders, capsules, lozenges, etc.
【0006】プロシアニジンは本発明の抗アレルギー剤
の全量中、0.005〜1重量%、好ましくは、0.0
1〜0.5重量%の割合になるように添加される。0.
005重量%未満では効果に乏しく、1重量%を越えて
配合しても効果の増加は望めない。抗アレルギー剤とし
ての投与量は疾患の症状、患者の年齢などにより異なる
が、通常、成人1日あたり30〜100mg、好ましく
は約50mgである。マウスを用いた急性毒性試験で
は、経口投与、皮下投与および静脈内投与とも2g/k
gで死亡例は認められなかった。また、剖検所見におい
ても、全ての臓器で異常は認められなかった。Procyanidin is an antiallergic agent of the present invention
In total amount, 0.005 wt%, preferably, 0.0
It is added in an amount of 1 to 0.5% by weight. 0.
If the amount is less than 005% by weight, the effect is poor, and if the amount exceeds 1% by weight, the effect cannot be expected to increase. The dose of the antiallergic agent varies depending on the symptoms of the disease, the age of the patient, etc., but is usually 30 to 100 mg, preferably about 50 mg per day for an adult. In an acute toxicity test using mice, both oral, subcutaneous and intravenous administration were 2 g / k
No deaths were observed in g. Moreover, no abnormalities were found in all organs in autopsy findings.
【0007】[0007]
【実施例】次に本発明を詳細に説明するため代表的な実
施例を挙げるが、本発明はこれに限定されるものではな
い。また、部とは重量部を示す。
製造例−1 プロシアニジンの精製
ウーロン茎茶に50倍量の水を加え、90〜95゜Cで1時間加
熱後濾過し、濾液を濃縮および凍結乾燥して熱水抽出物
を得た。この熱水抽出物1Kgを5Lの水に溶解し、2倍量
の酢酸エチルで3回分配抽出し、酢酸エチル画分を40g
得た。この酢酸エチル画分を水に溶解し、セファデック
スLH-20(ファルマシア社製)カラムクロマトグラフィ
ー(溶出液:0ー100%メタノール水溶液)に供した。得ら
れたカテキン画分を凍結乾燥後、再度水に溶解しMCIゲ
ル(三菱化成(株)製)カラムクロマトグラフィー(溶
出液:0ー100%メタノール水溶液)に供した。カテキン類
の溶出は、TLC分析(プレート:シリカゲル60、展開溶
媒:ベンゼン・ギ酸エチル・ギ酸(2:7:1)、発色薬:
アニスアルデヒドあるいは塩化第二鉄)により確認し、
1スポットを与える画分を集め、濃縮および凍結乾燥し
て(+)カテキンの8位と(ー)エピカテキンの4位が結合した
プロシアニジンB-1を250mg得た。また、同様にして、
(+)カテキンの4位と(-)エピカテキンの8位が結合したプ
ロシアニジンB-4を825mg得た。それぞれの構造は、比旋
光度及びNMRスペクトルを測定し、文献値と比較するこ
とにより同定した。EXAMPLES Next, typical examples will be given to explain the present invention in detail, but the present invention is not limited thereto. Moreover, a part shows a weight part. Production Example-1 Purified Procyanidin To oolong stem tea was added 50 times the amount of water, heated at 90 to 95 ° C for 1 hour and filtered, and the filtrate was concentrated and freeze-dried to obtain a hot water extract. 1 Kg of this hot water extract was dissolved in 5 L of water, and the mixture was extracted with 2 volumes of ethyl acetate three times to obtain 40 g of ethyl acetate fraction.
Obtained. This ethyl acetate fraction was dissolved in water and subjected to Sephadex LH-20 (Pharmacia) column chromatography (eluent: 0-100% methanol aqueous solution). The obtained catechin fraction was lyophilized, then dissolved again in water and subjected to MCI gel (manufactured by Mitsubishi Kasei Co., Ltd.) column chromatography (eluent: 0-100% methanol aqueous solution). Elution of catechins was performed by TLC analysis (plate: silica gel 60, developing solvent: benzene / ethyl formate / formic acid (2: 7: 1), chromogenic agent:
Anisaldehyde or ferric chloride)
Fractions giving one spot were collected, concentrated and lyophilized to obtain 250 mg of procyanidin B-1 in which the 8-position of (+) catechin and the 4-position of (−) epicatechin were bonded. Also, in the same way,
825 mg of procyanidin B-4 in which the 4-position of (+) catechin and the 8-position of (-) epicatechin were bonded was obtained. Each structure was identified by measuring specific rotation and NMR spectrum and comparing with literature values.
【0008】
実施例−1 キャンディー
マルチトール 48.0部
デンプン糖化物 20.0
プロシアニジン 0.1
[製法]120〜170゜Cで原料を加熱溶解し、金型にて固化
させる。Example-1 Candy maltitol 48.0 parts Starch saccharified product 20.0 Procyanidin 0.1 [Production Method] The raw materials are heated and melted at 120 to 170 ° C and solidified in a mold.
【0009】
実施例−2 ドロップ
砂糖 81.0部
D-グルコース 16.5
クエン酸 1.1
香料 適量
色素 適量
プロシアニジン 0.1
[製法]100〜120゜Cで原料を加熱溶解し、金型にて固化
させる。Example-2 Drop Sugar 81.0 parts D-Glucose 16.5 Citric acid 1.1 Fragrance Appropriate amount Colorant Appropriate amount procyanidin 0.1 [Production Method] The raw materials are heated and melted at 100 to 120 ° C and solidified in a mold.
【0010】 実施例−3 錠菓 白糖(微粉末) 100.0部 アラビアゴム(微粉末) 7.0 プロシアニジン 0.2 ハッカエキス 0.1 水 適量 [製法]原料をよく混合し、圧縮して製造する。[0010] Example-3 Tablet confectionery White sugar (fine powder) 100.0 parts Gum arabic (fine powder) 7.0 Procyanidins 0.2 Mint extract 0.1 Proper amount of water [Production method] The raw materials are mixed well and compressed to produce.
【0011】 実施例−4 チューイングガム ガムベース 20.0部 砂糖 78.5 プロシアニジン 0.1 ハッカエキス 1.0 水 適量 [製法]原料をよく混合し、常法にて製造する。[0011] Example-4 chewing gum Gum base 20.0 parts Sugar 78.5 Procyanidins 0.1 Mint extract 1.0 Proper amount of water [Manufacturing method] The raw materials are well mixed and manufactured by a conventional method.
【0012】
実施例−5 飲料
プロシアニジン 0.1部
安息香酸ナトリウム 0.1
果糖 1.0
香料 適量
色素 適量
精製水 全100.0
[製法]精製水に原料を加えて溶かし、精製水を加えて
全量を100.0部とする。Example-5 Beverage Procyanidin 0.1 part Sodium benzoate 0.1 Fructose 1.0 Fragrance Appropriate amount Dye Appropriate amount Purified water 100.0 [Production method] Raw materials are added to purified water to dissolve, and the total amount is adjusted to 100.0 parts.
【0013】
実施例−6 錠剤
プロシアニジン 1.0部
乳糖 99.0
乾燥コーンスターチ 2.0
タルク 1.8
ステアリン酸カルシウム 0.2
以上混和 200錠とする。一錠の重量0.52g
[製法]プロシアニジンに乳糖、乾燥コーンスターチを
加えて整粒し、タルク、ステアリン酸カルシウムなどの
滑沢剤を加えて混和し、打錠する。混合機は10分間運転
する。Example-6 Tablets Procyanidin 1.0 part Lactose 99.0 Dry cornstarch 2.0 Talc 1.8 Calcium stearate 0.2 or more Blended to give 200 tablets. Weight of one tablet 0.52 g [Production method] Lactose and dried cornstarch are added to procyanidin for sizing, and a lubricant such as talc and calcium stearate is added and mixed, and the mixture is tableted. Run the mixer for 10 minutes.
【0014】
実施例−7 顆粒剤
プロシアニジン 0.1部
乳糖 5.0
アラビアゴム末 1.0
単シロップ 適量
以上混和 顆粒剤200粒とする。
[製法]プロシアニジンを乳鉢にとり、少量の水に溶か
し、これにただちに乳糖を加えて、均密に研磨し、つい
でアラビアゴム末、最後に適量のシロップ液を少量ずつ
滴下し、乳棒で練り合わせて硬い可塑性の塊とし、これ
を顆粒器にかけて整粒する。Example 7 Granules Procyanidin 0.1 part Lactose 5.0 Gum arabic powder 1.0 Single syrup Admixed in appropriate amount or more 200 granules are prepared. [Production method] Put procyanidin in a mortar, dissolve in a small amount of water, immediately add lactose to this, grind evenly, then add gum arabic powder, and finally add an appropriate amount of syrup little by little and knead with a pestle to make a hard mixture. It is made into a plastic mass, and this is granulated by a granulator.
【0015】
実施例−8 散剤
プロシアニジン 0.1部
乳糖 9.0
以上混和 分12包散剤とする。
[製法]プロシアニジンを乳鉢にとり、少量の水に溶か
した後、乳糖を加えて均等になるまで研和し、乾燥後粉
砕して細末とする。Example-8 Powders Procyanidin 0.1 part Lactose 9.0 or more Admixture 12 powders. [Production method] Put procyanidins in a mortar, dissolve in a small amount of water, add lactose and grind until even, then dry and grind to give fine powder.
【0016】
実施例−9 カプセル剤
プロシアニジン 0.1部
微結晶セルロース 8.5
コーンスターチ 2.0
乳糖 2.2
ポリビニルピロリドン 0.3
以上混和 カプセル30個とする。
[製法]プロシアニジン、微結晶セルロース、コーンス
ターチおよび乳糖を混和し、ポリビニルピロリドンを結
合剤として加えて常法により顆粒化した後、ゼラチン硬
カプセルに充填した。Example-9 Capsule Preparation Procyanidin 0.1 part Microcrystalline Cellulose 8.5 Corn Starch 2.0 Lactose 2.2 Polyvinylpyrrolidone 0.3 or more Blended into 30 capsules. [Production Method] Procyanidin, microcrystalline cellulose, corn starch and lactose were mixed, polyvinylpyrrolidone was added as a binder, and the mixture was granulated by a conventional method and then filled into a gelatin hard capsule.
【0017】
実施例−10 トローチ剤
プロシアニジン 0.1部
ブドウ糖 100.0
炭酸水素ナトリウム 2.0
白糖末 4.0
アラビアゴム 3.0
デキストリン 1.0
以上混和 トローチ20個とする。
[製法]薬物をすべて研和して細末とし、水または単シ
ロップを少量ずつ加え、これを型に注入して20個に分割
する。白糖末を剤衣とする。Example-10 Lozenge Agent Procyanidin 0.1 part Glucose 100.0 Sodium hydrogencarbonate 2.0 White sugar powder 4.0 Gum arabic 3.0 Dextrin 1.0 or more 20 troches mixed with each other. [Manufacturing method] Grind all drugs into fine powder, add water or simple syrup little by little, and pour this into a mold to divide into 20 pieces. Sucrose powder is used as the clothing.
【0018】
実施例−11 点眼剤
プロシアニジン 0.1部
クロロブタノール 0.1
塩化ナトリウム 適量
精製水 全30.0
[製法]プロシアニジン、クロロブタノール、塩化ナト
リウムをそれぞれ秤量し、適量の精製水に溶解して全量
30部とする。Example-11 Eye Drops Procyanidin 0.1 part Chlorobutanol 0.1 Sodium Chloride Suitable amount Purified water 30.0 [Production Method] Procyanidin, chlorobutanol and sodium chloride were weighed and dissolved in suitable amount of purified water to obtain the total amount.
30 copies.
【0019】
実施例−12 シロップ剤
プロシアニジン 1.0部
カルボキシメチルセルロース 2.0
単シロップ 全100.0
[製法]まずカルボキシメチルセルロースを秤量し、乳
鉢内で均等の細末となるまで磨砕する。つぎに単シロッ
プの一部をとり、少量ずつ加えてよく研和して均等にす
る。これにプロシアニジンを徐々に加えて研和し、最後
に残余の単シロップを加え、均等の粘稠液とする。Example-12 Syrup Agent Procyanidin 1.0 part Carboxymethylcellulose 2.0 Single syrup Total 100.0 [Production Method] First, carboxymethylcellulose is weighed and ground in a mortar until it becomes a fine powder. Next, take a portion of the simple syrup, add little by little, and grind well to make it even. Gradually add procyanidin to the mixture and grind it, and finally add the remaining single syrup to make a uniform viscous liquid.
【0020】
実施例−13 注射剤
プロシアニジン 0.5部
クロロブタノール 0.5
塩化ナトリウム 0.9
注射用蒸留水 全100.0
[製法]蒸留水をあたためてクロロブタノールを溶か
し、これに塩化ナトリウムおよびプロシアニジンを加え
て溶かし、蒸留水を加えて全量を 100.0部とする。濾過
してバイアルビンに入れ熔閉した後、 121゜Cで15分間滅
菌する。Example-13 Injection Procyanidin 0.5 parts Chlorobutanol 0.5 Sodium chloride 0.9 Distilled water for injection All 100.0 [Production Method] Distilled water was dissolved by dissolving warm chlorobutanol, and sodium chloride and procyanidin were added to the solution. Is added to make the total amount 100.0 parts. Filter, put in a vial, seal, and sterilize at 121 ° C for 15 minutes.
【0021】
実施例−14 坐剤
プロシアニジン 1.0部
カーボワックス4000 20.0
カーボワックス1500 90.0
以上坐剤70個とする。
[製法]プロシアニジンを乳鉢にとり細末とし、これに
溶融して混合したカーボワックスを少量ずつ加えながら
研和し、坐剤型に流し込む。Example-14 Suppository Procyanidin 1.0 part Carbowax 4000 20.0 Carbowax 1500 90.0 or more 70 suppositories are used. [Production method] Procyanidin is placed in a mortar, made into fine powder, and the melted and mixed carbowax is added little by little to be ground and poured into a suppository mold.
【0022】
実施例−15 軟膏
プロシアニジン 1.0部
流動パラフィン 10.0
白色ワセリン 全100.0
[製法]プロシアニジンを流動パラフィンと研和して泥
状とし、白色ワセリンを混和練り合わせて均質として製
する。Example-15 Ointment Procyanidin 1.0 part Liquid paraffin 10.0 White petrolatum 100.0 [Production method] Procyanidin is ground with liquid paraffin to form a mud, and white petrolatum is mixed and kneaded to prepare a homogeneous product.
【0023】
実施例−16 キャンディー
マルチトール 48.0部
デンプン糖化物 20.0
プロシアニジンB-1 0.1
[製法]120〜170゜Cで原料を加熱溶解し、金型にて固化
させる。Example-16 Candy Maltitol 48.0 parts Starch saccharified product 20.0 Procyanidin B-1 0.1 [Production Method] The raw materials are heated and melted at 120 to 170 ° C and solidified in a mold.
【0024】
実施例−17 ドロップ
砂糖 81.0部
D-グルコース 16.5
クエン酸 1.1
香料 適量
色素 適量
プロシアニジンB-1 0.1
[製法]100〜120゜Cで原料を加熱溶解し、金型にて固化
させる。Example-17 Drop Sugar 81.0 parts D-Glucose 16.5 Citric acid 1.1 Fragrance Appropriate amount Dye Appropriate amount Procyanidin B-1 0.1 [Production Method] The raw materials are heated and dissolved at 100 to 120 ° C. and solidified in a mold.
【0025】 実施例−18 錠菓 白糖(微粉末) 100.0部 アラビアゴム(微粉末) 7.0 プロシアニジンB-1 0.2 ハッカエキス 0.1 水 適量 [製法]原料をよく混合し、圧縮して製造する。[0025] Example-18 Tablet confectionery White sugar (fine powder) 100.0 parts Gum arabic (fine powder) 7.0 Procyanidin B-1 0.2 Mint extract 0.1 Proper amount of water [Production method] The raw materials are mixed well and compressed to produce.
【0026】 実施例−19 チューイングガム ガムベース 20.0部 砂糖 78.5 プロシアニジンB-1 0.1 ハッカエキス 1.0 水 適量 [製法]原料をよく混合し、常法にて製造する。[0026] Example-19 Chewing gum Gum base 20.0 parts Sugar 78.5 Procyanidin B-1 0.1 Mint extract 1.0 Proper amount of water [Manufacturing method] The raw materials are well mixed and manufactured by a conventional method.
【0027】
実施例−20 飲料
プロシアニジンB-1 0.1部
安息香酸ナトリウム 0.1
果糖 1.0
香料 適量
色素 適量
精製水 全100.0
[製法]精製水に原料を加えて溶かし、精製水を加えて
全量を100.0部とする。Example-20 Beverage Procyanidin B-1 0.1 part Sodium benzoate 0.1 Fructose 1.0 Fragrance Suitable amount Colorant Suitable amount Purified water 100.0 [Production Method] Raw materials were added to purified water to dissolve, and total amount was 100.0 parts To do.
【0028】
実施例−21 錠剤
プロシアニジンB-1 1.0部
乳糖 99.0
乾燥コーンスターチ 2.0
タルク 1.8
ステアリン酸カルシウム 0.2
以上混和 200錠とする。一錠の重量0.52g
[製法]プロシアニジンB-1に乳糖、乾燥コーンスター
チを加えて整粒し、タルク、ステアリン酸カルシウムな
どの滑沢剤を加えて混和し、打錠する。混合機は10分間
運転する。Example-21 Tablet Procyanidin B-1 1.0 part Lactose 99.0 Dry cornstarch 2.0 Talc 1.8 Calcium stearate 0.2 or more Blend 200 tablets. Weight of one tablet 0.52 g [Production method] Lactose and dried cornstarch are added to procyanidin B-1 for sizing, and a lubricant such as talc and calcium stearate is added, mixed, and compressed. Run the mixer for 10 minutes.
【0029】
実施例−22 顆粒剤
プロシアニジンB-1 0.1部
乳糖 5.0
アラビアゴム末 1.0
単シロップ 適量
以上混和 顆粒剤200粒とする。
[製法]プロシアニジンB-1を乳鉢にとり、少量の水に
溶かし、これにただちに乳糖を加えて、均密に研磨し、
ついでアラビアゴム末、最後に適量のシロップ液を少量
ずつ滴下し、乳棒で練り合わせて硬い可塑性の塊とし、
これを顆粒器にかけて整粒する。Example-22 Granules Procyanidin B-1 0.1 part Lactose 5.0 Gum arabic powder 1.0 Single syrup Admixed in appropriate amount or more 200 granules are prepared. [Manufacturing method] Put procyanidin B-1 in a mortar, dissolve in a small amount of water, immediately add lactose to this, and polish uniformly.
Then add gum arabic powder, and finally add an appropriate amount of syrup little by little and knead with a pestle to make a hard plastic mass,
This is put into a granulator and sized.
【0030】
実施例−23 散剤
プロシアニジンB-1 0.1部
乳糖 9.0
以上混和 分12包散剤とする。
[製法]プロシアニジンB-1を乳鉢にとり、少量の水に
溶かした後、乳糖を加えて均等になるまで研和し、乾燥
後粉砕して細末とする。Example-23 Powder Procyanidin B-1 0.1 part Lactose 9.0 or more Admixture 12 powder mixture. [Production method] Put procyanidin B-1 in a mortar, dissolve in a small amount of water, add lactose and grind until uniform, dry and grind to give fine powder.
【0031】
実施例−24 カプセル剤
プロシアニジンB-1 0.1部
微結晶セルロース 8.5
コーンスターチ 2.0
乳糖 2.2
ポリビニルピロリドン 0.3
以上混和 カプセル30個とする。
[製法]プロシアニジンB-1、微結晶セルロース、コー
ンスターチおよび乳糖を混和し、ポリビニルピロリドン
を結合剤として加えて常法により顆粒化した後、ゼラチ
ン硬カプセルに充填した。Example-24 Capsule Preparation Procyanidin B-1 0.1 Part Microcrystalline Cellulose 8.5 Corn Starch 2.0 Lactose 2.2 Polyvinylpyrrolidone 0.3 or more Mixture 30 capsules are prepared. [Production Method] Procyanidin B-1, microcrystalline cellulose, corn starch and lactose were mixed, polyvinylpyrrolidone was added as a binder, and the mixture was granulated by a conventional method and then filled into a gelatin hard capsule.
【0032】
実施例−25 トローチ剤
プロシアニジンB-1 0.1部
ブドウ糖 100.0
炭酸水素ナトリウム 2.0
白糖末 4.0
アラビアゴム 3.0
デキストリン 1.0
以上混和 トローチ20個とする。
[製法]薬物をすべて研和して細末とし、水または単シ
ロップを少量ずつ加え、これを型に注入して20個に分割
する。白糖末を剤衣とする。Example-25 Lozenge Agent Procyanidin B-1 0.1 part Glucose 100.0 Sodium hydrogencarbonate 2.0 White sugar powder 4.0 Gum arabic 3.0 Dextrin 1.0 or more 20 troches mixed with each other are used. [Manufacturing method] Grind all drugs into fine powder, add water or simple syrup little by little, and pour this into a mold to divide into 20 pieces. Sucrose powder is used as the clothing.
【0033】
実施例−26 点眼剤
プロシアニジンB-1 0.1部
クロロブタノール 0.1
塩化ナトリウム 適量
精製水 全30.0
[製法]プロシアニジンB-1、クロロブタノール、塩化
ナトリウムをそれぞれ秤量し、適量の精製水に溶解して
全量30部とする。Example-26 Eye Drops Procyanidin B-1 0.1 part Chlorobutanol 0.1 Sodium chloride suitable amount Purified water 30.0 [Production Method] Procyanidin B-1, chlorobutanol and sodium chloride were weighed and dissolved in appropriate amount of purified water. The total amount is 30 copies.
【0034】
実施例−27 シロップ剤
プロシアニジンB-1 1.0部
カルボキシメチルセルロース 2.0
単シロップ 全100.0
[製法]まずカルボキシメチルセルロースを秤量し、乳
鉢内で均等の細末となるまで磨砕する。つぎに単シロッ
プの一部をとり、少量ずつ加えてよく研和して均等にす
る。これにプロシアニジンB-1を徐々に加えて研和し、
最後に残余の単シロップを加え、均等の粘稠液とする。Example-27 Syrup Agent Procyanidin B-1 1.0 part Carboxymethylcellulose 2.0 Single syrup Total 100.0 [Production Method] First, carboxymethylcellulose is weighed and ground in a mortar until it becomes a fine powder. Next, take a portion of the simple syrup, add little by little, and grind well to make it even. Gradually add procyanidin B-1 to this,
Finally, add the remaining single syrup to make a uniform viscous liquid.
【0035】
実施例−28 注射剤
プロシアニジンB-1 0.5部
クロロブタノール 0.5
塩化ナトリウム 0.9
注射用蒸留水 全100.0
[製法]蒸留水をあたためてクロロブタノールを溶か
し、これに塩化ナトリウムおよびプロシアニジンB-1を
加えて溶かし、蒸留水を加えて全量を 100.0部とする。
濾過してバイアルビンに入れ熔閉した後、 121゜Cで15分
間滅菌する。Example-28 Injectable preparation Procyanidin B-1 0.5 part Chlorobutanol 0.5 Sodium chloride 0.9 Distilled water for injection Total 100.0 [Production Method] Distilled water was warmed to dissolve chlorobutanol, and sodium chloride and procyanidin B-1 were added thereto. In addition, dissolve and add distilled water to make the total volume 100.0 parts.
Filter, put in a vial, seal, and sterilize at 121 ° C for 15 minutes.
【0036】
実施例−29 坐剤
プロシアニジンB-1 1.0部
カーボワックス4000 20.0
カーボワックス1500 90.0
以上坐剤70個とする。
[製法]プロシアニジンB-1を乳鉢にとり細末とし、こ
れに溶融して混合したカーボワックスを少量ずつ加えな
がら研和し、坐剤型に流し込む。Example-29 Suppository Procyanidin B-1 1.0 part Carbowax 4000 20.0 Carbowax 1500 90.0 More than 70 suppositories. [Production Method] Procyanidin B-1 is placed in a mortar, made into fine powder, and the carbowax which is melted and mixed is added little by little to be ground and poured into a suppository mold.
【0037】
実施例−30 軟膏
プロシアニジンB-1 1.0部
流動パラフィン 10.0
白色ワセリン 全100.0
[製法]プロシアニジンB-1を流動パラフィンと研和し
て泥状とし、白色ワセリンを混和練り合わせて均質とし
て製する。Example-30 Ointment Procyanidin B-1 1.0 part Liquid paraffin 10.0 White petrolatum 100.0 [Production method] Procyanidin B-1 was ground with liquid paraffin to form a mud, and white petrolatum was kneaded and kneaded to prepare a homogeneous product. .
【0038】本発明によれば、プロシアニジンを主成分
とする強い効果を有する抗アレルギー剤を提供すること
が可能となる。本成分はおもに茶から得られ、日常常用
しているものであるので、安全性も高い。また、プロシ
アニジンは他のカテキン類に比べ、安定性に優れており
製剤化が容易であった。つぎに、本発明の効果を詳細に
説明するため、実験例を挙げる。According to the present invention, procyanidin is the main component.
It is possible to provide an antiallergic agent having a strong effect of Since this ingredient is mainly obtained from tea and is used daily, it is highly safe. Further, procyanidins were superior in stability to other catechins and were easy to formulate. Next, in order to explain the effect of the present invention in detail, an experimental example will be given.
【0039】実験例−1 ヒスタミン遊離抑制作用
Sprague-Dawley系雄性ラットの腹腔内から採取した肥満
細胞を用いてヒスタミン遊離抑制作用を検討した。すな
わち、単離した肥満細胞をIgE抗体で感作させ、卵白ア
ルブミン刺激により遊離するヒスタミン量を測定した。
肥満細胞はSullivanらの方法( J.Immunology, 114(5),
1473-1479,1975)で採取し、ヒスタミンの定量はMayら
の方法( J.Allergy, 46,12-20,1970 )で行った。結果
は表1に示すとおり、プロシアニジンは強いヒスタミン
遊離抑制作用を示し、特に、プロシアニジンB-1はエピ
ガロカテキンガレートよりも高い抑制率を示した。
以下余白Experimental Example 1 Histamine Release Inhibitory Effect The histamine release inhibitory effect was examined using mast cells collected from the abdominal cavity of Sprague-Dawley male rats. That is, the isolated mast cells were sensitized with an IgE antibody, and the amount of histamine released by ovalbumin stimulation was measured.
Mast cells are derived from the method of Sullivan et al. (J. Immunology, 114 (5),
1473-1479, 1975), and histamine was quantified by the method of May et al. (J. Allergy, 46, 12-20, 1970). As shown in Table 1, procyanidins showed a strong histamine release inhibitory effect, and procyanidin B-1 showed a higher inhibitory rate than epigallocatechin gallate. Margin below
【0040】[0040]
【表1】
実験例−2 使用試験
アレルギー性鼻炎あるいは花粉症に悩む被験者52名に対
して、実施例−16のキャンディーの使用試験を行っ
た。被験者には実施例−16のキャンディーを、これと
は別の8名に実施例−16からプロシアニジンB-1を除
いたキャンディー(比較例−1)をそれぞれ1日に3〜
5個食し、2ヶ月後に改善度について調べた。その結
果、比較例−1では8名中1名(12.5%)に改善が認めら
れたのに対して、実施例−16においては52名中38名(7
3.1%)に症状の改善が認められた。[Table 1] Experimental Example-2 Usage Test A usage test of the candy of Example-16 was conducted on 52 subjects suffering from allergic rhinitis or hay fever. The test subject was the candy of Example-16, and eight other subjects were candy obtained by removing procyanidin B-1 from Example-16 (Comparative Example-1) for 3 to 1 day each.
Five meals were eaten and the degree of improvement was examined 2 months later. As a result, in Comparative Example-1, improvement was observed in 1 out of 8 persons (12.5%), whereas in Example-16, 38 out of 52 persons (7
Improvement of symptoms was observed in 3.1%).
【0041】実験例−3 使用試験
アレルギー性鼻炎あるいは花粉症に悩む被験者61名に対
して、実施例−25のトローチの使用試験を行った。被
検者には実施例−25のトローチを、これとは別の8名
に実施例−25からプロシアニジンB-1を除いたトロー
チ(比較例−2)をそれぞれ1日に3〜5個食し、2カ
月後に改善度について調べた。その結果、比較例−2で
は改善が認められなかったのに対して、実施例−25に
おいては61名中43名(70.5%)に症状の改善が認められ
た。Experimental Example-3 Use Test The use test of the troche of Example-25 was conducted on 61 subjects suffering from allergic rhinitis or hay fever. To the subject, the lozenge of Example-25 was eaten, and to another 8 persons, 3 to 5 lozenges (Comparative Example-2) excluding procyanidin B-1 from Example-25 were eaten per day. After 2 months, the degree of improvement was examined. As a result, in Comparative Example-2, no improvement was observed, whereas in Example-25, 43 of 61 (70.5%) showed improvement in symptoms.
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) A23L 1/30 A61K 35/78 A61K 31/35 JICSTファイル(JOIS)─────────────────────────────────────────────────── ─── Continuation of the front page (58) Fields surveyed (Int.Cl. 7 , DB name) A23L 1/30 A61K 35/78 A61K 31/35 JISST file (JOIS)
Claims (2)
る抗アレルギー剤。Anti-allergic agent.
徴とする抗アレルギー剤。Antiallergic agent to be taken.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP03752395A JP3450080B2 (en) | 1995-02-01 | 1995-02-01 | Health foods and pharmaceuticals containing procyanidin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP03752395A JP3450080B2 (en) | 1995-02-01 | 1995-02-01 | Health foods and pharmaceuticals containing procyanidin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08205818A JPH08205818A (en) | 1996-08-13 |
| JP3450080B2 true JP3450080B2 (en) | 2003-09-22 |
Family
ID=12499912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP03752395A Expired - Fee Related JP3450080B2 (en) | 1995-02-01 | 1995-02-01 | Health foods and pharmaceuticals containing procyanidin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3450080B2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777005B1 (en) * | 1994-10-03 | 2004-08-17 | Mars, Incorporated | Foods containing a cocoa polyphenol additive |
| US5554645A (en) | 1994-10-03 | 1996-09-10 | Mars, Incorporated | Antineoplastic cocoa extracts and methods for making and using the same |
| JPH09291039A (en) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | Antiobestic medicine comprising procyanidin as active ingredient |
| US7968140B2 (en) | 1997-09-08 | 2011-06-28 | Mars, Incorporated | Chocolates and chocolate liquor having an enhanced polyphenol content |
| BR9908721A (en) * | 1998-03-12 | 2001-10-30 | Mars Inc | Products containing polyphenol (ois) and l-arginine to stimulate nitric oxide production |
| US8507018B2 (en) | 1998-03-12 | 2013-08-13 | Mars, Incorporated | Products containing polyphenol(s) and L-arginine and methods of use thereof |
| US6805883B2 (en) | 1998-03-12 | 2004-10-19 | Mars, Incorporated | Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide |
| KR100509119B1 (en) * | 1999-07-16 | 2005-08-18 | 주식회사 엘지생활건강 | Medicine comprising procyanidine as an effective agent |
| JP2001158739A (en) * | 1999-09-21 | 2001-06-12 | Kyowa Hakko Kogyo Co Ltd | Composition containing proanthocyanidin and vitamin B6 derivative or salt thereof |
| ITMI20032287A1 (en) * | 2003-11-24 | 2005-05-25 | Indena Spa | COMPOSITIONS FOR THE TREATMENT OF THE ORAL CABLE AFFECTIONS AND THE FIRST RESPIRATORY ROUTES |
| JP4788994B2 (en) * | 2005-01-26 | 2011-10-05 | 独立行政法人農業・食品産業技術総合研究機構 | Functional food and drink |
| JP4942953B2 (en) * | 2005-06-30 | 2012-05-30 | サントリーホールディングス株式会社 | Analysis method of procyanidins |
| CN102432578B (en) * | 2011-11-18 | 2015-06-10 | 北京宝得瑞食品有限公司 | Method for extracting proanthocyanidins from seabuckthorm seeds |
-
1995
- 1995-02-01 JP JP03752395A patent/JP3450080B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08205818A (en) | 1996-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3450080B2 (en) | Health foods and pharmaceuticals containing procyanidin | |
| US8574633B2 (en) | Huperzia serrata (Thunb.) Trev. composition comprising compounded Huperzine A and Huperzine B and methods for preparing it | |
| WO2013139111A1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
| EP0370284B1 (en) | A composition containing an extract obtained by a watercontaining organic solvent, and a process for preparing the same | |
| US20110159122A1 (en) | Combination of extracts of various plants for improving the symptoms of dementia disorders | |
| JP3968405B2 (en) | Antiallergic agent | |
| GB2173500A (en) | Benz (b)indeno (2, 1-d)pyran drugs | |
| EP2172206A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| TWI673059B (en) | IL-6 production inhibitor, anti-inflammatory agent, anti-neurodegenerative disease agent, anti-psychiatric agent, pharmaceutical | |
| JP2001114686A (en) | Th2 CYTOKININ EXPRESSION SUPPRESSANT | |
| KR100979459B1 (en) | Daychu Extract Increases Glucose Absorption in Muscle Cells and 4H-Chromen-4-one Derivatives | |
| JP3159508B2 (en) | Health foods and pharmaceuticals containing oolong stem tea extract | |
| JP3204348B2 (en) | Arteriosclerosis inhibitor and food or medicine containing it | |
| JPH07255419A (en) | Health food and medicine mixed with (+) catechin | |
| JPH08242813A (en) | Health food and medicine blended with gallocatechin gallate | |
| WO2004035074A1 (en) | Composition for lowering blood glucose level comprising extract of natural product | |
| JP2788166B2 (en) | Composition for eliminating active oxygen | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same | |
| JPH04124139A (en) | Hypoglycemically functioning agent and its production | |
| JPH07267864A (en) | Hypothermia | |
| JP3621483B2 (en) | Histamine release inhibitor | |
| EP2277525A1 (en) | A method for preparing extractive containing sequoyitol from nephrolepis family and application | |
| JP3059243B2 (en) | Anti-ulcer agent | |
| JP2000116356A (en) | Antiallergic food and antiallergic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090711 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120711 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130711 Year of fee payment: 10 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |